Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
about
Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients.Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning.Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patientsAn analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation.Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults.Predictive performance of a physiologically based pharmacokinetic model of busulfan in children.GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation.Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.Development of multiplex PCR method for the analysis of glutathione s-transferase polymorphism.Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation.Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients.The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
P2860
Q33558113-7EE597BB-2366-4A55-9C83-43019A2D3833Q33687277-C0C46DE6-2D21-494D-9B35-C9E99F82D41DQ35053340-E3C59002-D33C-46C9-A1DA-A3278073E37CQ35861851-376E6D75-8AAF-422E-BE4D-8B21494A87DBQ36650481-978DC172-9522-4866-917D-3239AA2EC7DBQ38372455-5D68AC92-94D6-4D10-BD90-D23F84FB791AQ38847841-D8F07438-4759-4FED-A392-A2292C11C948Q39490930-C92AC74E-3C02-4784-9851-31021117854CQ40085411-4BB261AE-C314-4725-B699-BB84862778A0Q44395207-82C2849E-8549-4B30-B093-E7857DBD8AC4Q44419087-437DF020-CE4F-48D5-8329-B1E2EE222852Q45948328-2181BDDD-F99B-420A-90B7-10ECF9E33173Q47968881-1EF47D29-91E9-4F8C-BFB9-A79EDD6B09CBQ47972996-3693BBB6-4AB5-4BF7-9F82-C1805BB23C43Q50802622-1B017AD2-6E4C-4522-9D4A-310CE78DBB1FQ52552920-F4B8FB93-0565-48D3-96AC-905356745095Q52613271-CFE5AA47-FF23-4F26-8C86-AF6E454C9C79Q52690736-72945618-F654-453A-9CB2-C5045DD271C0Q53399897-83F2F02B-D110-4126-984F-2166BE3D0B11Q54659626-ADD1DCB6-8C1F-49E9-8109-C8BAE3E62553Q54671417-58994E36-0C63-466A-BBFE-3DC5C7B23625Q54686050-0BE45F30-7FAB-462E-8112-843A7215E9E4Q58789022-CB268F0F-5DC3-4A10-8D6F-93B26FF03E41
P2860
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
@en
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
@nl
type
label
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
@en
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
@nl
prefLabel
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
@en
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
@nl
P2093
P2860
P356
P1476
Influence of GST gene polymorphisms on busulfan pharmacokinetics in children
@en
P2093
M A Champagne
M Krajinovic
M-F Vachon
P2860
P2888
P304
P356
10.1038/BMT.2009.143
P407
P577
2009-07-06T00:00:00Z
P5875
P6179
1025986947